XML 61 R46.htm IDEA: XBRL DOCUMENT v3.19.1
Acquisition of Icon Bioscience, Inc - Additional Information (Detail) - USD ($)
 6 Months Ended
Mar. 28, 2018
Dec. 31, 2018
DEXYCU [Member]    
Business Acquisition [Line Items]    
Finite-lived intangible asset expected amortization life   12 years 3 months
Icon Bioscience Inc [Member]    
Business Acquisition [Line Items]    
Acquisition date Mar. 28, 2018  
Consideration payment at closing $ 15,000,000  
Estimated working capital adjustment at closing (127,000)  
Development milestone payment due upon first commercial sales of DEXYCU 15,000,000 $ 15,000,000
Maximum of potential sales milestone payments $ 95,000,000  
Quarterly percentage earn-out consideration due on product net sales 12.00%  
Increased percentage earn-out on product net sales if net sales and partnering revenue exceed $200 million in a given year 16.00%  
Contingent cash payments, description   These include but are not limited to (i) a one-time development milestone of $15.0 million payable in cash upon the first commercial sale of DEXYCU in the U.S., (ii) sales milestone payments totaling up to $95.0 million upon the achievement of certain sales thresholds and subject to certain Centers for Medicare & Medicaid Services (“CMS”) reimbursement conditions set forth in the Merger Agreement, (iii) quarterly earn-out payments equal to 12% on net sales of DEXYCU in a given year, which earn-out payments will increase to 16% of net sales of DEXYCU in such year beginning in the calendar quarter for such year to the extent aggregate annual consideration of DEXYCU exceeds $200.0 million in such year, (iv) quarterly earn-out payments equal to 20% of partnering revenue received by the Company for DEXYCU outside of the U.S., and (v) single-digit percentage quarterly earn-out payments with respect to net sales and/or partnering income, if any, resulting from future clinical development, regulatory approval and commercialization of any other product candidates the Company acquired in the Icon Acquisition.
Purchase price of acquisition $ 32,000,000  
Transaction costs 2,000,000  
Icon Bioscience Inc [Member] | DEXYCU [Member]    
Business Acquisition [Line Items]    
Purchase price of acquisition $ 32,000,000  
Finite-lived intangible asset expected amortization life 13 years  
Icon Bioscience Inc [Member] | Minimum [Member]    
Business Acquisition [Line Items]    
Threshold level of annual aggregate consideration above which the 16% royalty on net sales applies in any given year $ 200,000,000  
Icon Bioscience Inc [Member] | Non-US [Member]    
Business Acquisition [Line Items]    
Percentage of partnering income received to be paid quarterly as earn-out consideration 20.00%